{"id":"https://openalex.org/W4398250556","doi":"https://doi.org/10.1182/bloodadvances.2023012424","title":"Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis","display_name":"Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis","publication_year":2024,"publication_date":"2024-05-23","ids":{"openalex":"https://openalex.org/W4398250556","doi":"https://doi.org/10.1182/bloodadvances.2023012424","pmid":"https://pubmed.ncbi.nlm.nih.gov/38781315","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/11399641"},"language":"en","primary_location":{"id":"doi:10.1182/bloodadvances.2023012424","doi":"https://doi.org/10.1182/bloodadvances.2023012424","is_oa":true,"landing_page_url":"https://doi.org/10.1182/bloodadvances.2023012424","pdf_url":null,"source":{"id":"https://openalex.org/S2764683450","display_name":"Blood Advances","issn_l":"2473-9529","issn":["2473-9529","2473-9537"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Advances","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1182/bloodadvances.2023012424","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100438316","display_name":"Michael L. Wang","orcid":"https://orcid.org/0000-0001-9748-5486","observed_orcids":["https://orcid.org/0000-0001-9748-5486"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Michael Wang","raw_affiliation_strings":["1Department of Lymphoma/Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center, The University of Texas, Houston, TX"],"raw_orcid":"https://orcid.org/0000-0001-9748-5486","affiliations":[{"raw_affiliation_string":"1Department of Lymphoma/Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center, The University of Texas, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087571749","display_name":"Tadeusz Robak","orcid":"https://orcid.org/0000-0002-3411-6357","observed_orcids":["https://orcid.org/0000-0002-3411-6357"]},"institutions":[{"id":"https://openalex.org/I4210110173","display_name":"Copernicus Memorial Hospital","ror":"https://ror.org/01m32d953","country_code":"PL","type":"healthcare","lineage":["https://openalex.org/I4210110173"]},{"id":"https://openalex.org/I4210122071","display_name":"Medical University of Lodz","ror":"https://ror.org/02t4ekc95","country_code":"PL","type":"education","lineage":["https://openalex.org/I4210122071"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Tadeusz Robak","raw_affiliation_strings":["2Department of Hematology, Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland"],"raw_orcid":"https://orcid.org/0000-0002-3411-6357","affiliations":[{"raw_affiliation_string":"2Department of Hematology, Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland","institution_ids":["https://openalex.org/I4210110173","https://openalex.org/I4210122071"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024389256","display_name":"Kami J. Maddocks","orcid":"https://orcid.org/0000-0001-8519-8404","observed_orcids":["https://orcid.org/0000-0001-8519-8404"]},"institutions":[{"id":"https://openalex.org/I2799885155","display_name":"The Ohio State University Comprehensive Cancer Center \u2013 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute","ror":"https://ror.org/028t46f04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799885155","https://openalex.org/I2802841970"]},{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kami J. Maddocks","raw_affiliation_strings":["3Division of Hematology, The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Division of Hematology, The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH","institution_ids":["https://openalex.org/I2799885155","https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062534813","display_name":"Tycel Jovelle Phillips","orcid":"https://orcid.org/0000-0003-2143-9672","observed_orcids":["https://orcid.org/0000-0003-2143-9672"]},"institutions":[{"id":"https://openalex.org/I27837315","display_name":"University of Michigan","ror":"https://ror.org/00jmfr291","country_code":"US","type":"education","lineage":["https://openalex.org/I27837315"]},{"id":"https://openalex.org/I4390039285","display_name":"U-M Rogel Cancer Center","ror":"https://ror.org/05asdy483","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210114445","https://openalex.org/I4390039285"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tycel Phillips","raw_affiliation_strings":["4University of Michigan Comprehensive Cancer Center, Ann Arbor, MI"],"raw_orcid":"https://orcid.org/0000-0003-2143-9672","affiliations":[{"raw_affiliation_string":"4University of Michigan Comprehensive Cancer Center, Ann Arbor, MI","institution_ids":["https://openalex.org/I27837315","https://openalex.org/I4390039285"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Stephen D. Smith","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1332479046","display_name":"Seattle Cancer Care Alliance","ror":"https://ror.org/03jq88n71","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1332479046"]},{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen D. Smith","raw_affiliation_strings":["5University of Washington/Fred Hutchinson Cancer Center, Seattle, WA","University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5University of Washington/Fred Hutchinson Cancer Center, Seattle, WA","institution_ids":["https://openalex.org/I201448701","https://openalex.org/I4210089486"]},{"raw_affiliation_string":"University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States","institution_ids":["https://openalex.org/I1332479046","https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113225676","display_name":"David H. Gallinson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100668","display_name":"Summit Medical Group (United States)","ror":"https://ror.org/017bzf706","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100668"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Gallinson","raw_affiliation_strings":["6Summit Medical Group, Florham Park, NJ","Summit Medical Group, Florham Park, New Jersey, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Summit Medical Group, Florham Park, NJ","institution_ids":["https://openalex.org/I4210100668"]},{"raw_affiliation_string":"Summit Medical Group, Florham Park, New Jersey, United States","institution_ids":["https://openalex.org/I4210100668"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110884126","display_name":"Roser Calvo","orcid":"https://orcid.org/0000-0001-6217-846X","observed_orcids":["https://orcid.org/0000-0001-6217-846X"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Roser Calvo","raw_affiliation_strings":["7AstraZeneca, Gaithersburg, MD","AstraZeneca, Gaithersburg, Maryland, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7AstraZeneca, Gaithersburg, MD","institution_ids":["https://openalex.org/I4210150756"]},{"raw_affiliation_string":"AstraZeneca, Gaithersburg, Maryland, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110814878","display_name":"Chuan\u2010Chuan Wun","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chuan-Chuan Wun","raw_affiliation_strings":["8AstraZeneca, South San Francisco, CA","AstraZeneca, South San Francisco,, California, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8AstraZeneca, South San Francisco, CA","institution_ids":["https://openalex.org/I4210150756"]},{"raw_affiliation_string":"AstraZeneca, South San Francisco,, California, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050633601","display_name":"Veerendra Munugalavadla","orcid":"https://orcid.org/0000-0002-2390-3822","observed_orcids":["https://orcid.org/0000-0002-2390-3822"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Veerendra Munugalavadla","raw_affiliation_strings":["8AstraZeneca, South San Francisco, CA","AstraZeneca, South San Francisco, California, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8AstraZeneca, South San Francisco, CA","institution_ids":["https://openalex.org/I4210150756"]},{"raw_affiliation_string":"AstraZeneca, South San Francisco, California, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5102788725","display_name":"Wojciech J. Jurczak","orcid":"https://orcid.org/0000-0003-1879-8084","observed_orcids":["https://orcid.org/0000-0003-1879-8084"]},"institutions":[{"id":"https://openalex.org/I4210150880","display_name":"The Maria Sklodowska-Curie National Research Institute of Oncology","ror":"https://ror.org/04qcjsm24","country_code":"PL","type":"healthcare","lineage":["https://openalex.org/I4210150880"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Wojciech Jurczak","raw_affiliation_strings":["9Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland"],"raw_orcid":"https://orcid.org/0000-0003-1879-8084","affiliations":[{"raw_affiliation_string":"9Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland","institution_ids":["https://openalex.org/I4210150880"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":13,"corresponding_author_ids":["https://openalex.org/A5100438316"],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":{"value":3000,"currency":"USD","value_usd":3000},"apc_paid":{"value":3000,"currency":"USD","value_usd":3000},"fwci":10.1432,"has_fulltext":true,"cited_by_count":27,"citation_normalized_percentile":{"value":0.9875793,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"8","issue":"17","first_page":"4539","last_page":"4548"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0020000000949949026,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12212","display_name":"CNS Lymphoma Diagnosis and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mantle-cell-lymphoma","display_name":"mantle cell lymphoma","score":0.878000020980835},{"id":"https://openalex.org/keywords/acalabrutinib","display_name":"acalabrutinib","score":0.9599999785423279},{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":1.0},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.7649999856948853},{"id":"https://openalex.org/keywords/covid-19-infection","display_name":"COVID-19 infection","score":0.7480000257492065},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.7149999737739563},{"id":"https://openalex.org/keywords/minimal-residual-disease-negativity","display_name":"minimal residual disease negativity","score":0.7950000166893005},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9169999957084656},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.925000011920929},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.6710000038146973},{"id":"https://openalex.org/keywords/chemotherapy-free-regimen","display_name":"chemotherapy-free regimen","score":0.7689999938011169},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.47999998927116394},{"id":"https://openalex.org/keywords/atrial-fibrillation","display_name":"atrial fibrillation","score":0.6959999799728394},{"id":"https://openalex.org/keywords/ventricular-tachyarrhythmia","display_name":"ventricular tachyarrhythmia","score":0.8050000071525574}],"concepts":[{"id":"https://openalex.org/C2777525834","wikidata":"https://www.wikidata.org/wiki/Q268713","display_name":"Mantle cell lymphoma","level":3,"score":0.8287703990936279},{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.7860034704208374},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.7129322290420532},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.6089808344841003},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4741743803024292},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3965272307395935},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.36593496799468994},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.33671456575393677},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.12188464403152466},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.07024449110031128}],"mesh":[{"descriptor_ui":"D000069283","descriptor_name":"Rituximab","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000069283","descriptor_name":"Rituximab","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000069283","descriptor_name":"Rituximab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000086382","descriptor_name":"COVID-19","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D000086402","descriptor_name":"SARS-CoV-2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019086","descriptor_name":"Bridged Bicyclo Compounds, Heterocyclic","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D019086","descriptor_name":"Bridged Bicyclo Compounds, Heterocyclic","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D019086","descriptor_name":"Bridged Bicyclo Compounds, Heterocyclic","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D020522","descriptor_name":"Lymphoma, Mantle-Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1182/bloodadvances.2023012424","doi":"https://doi.org/10.1182/bloodadvances.2023012424","is_oa":true,"landing_page_url":"https://doi.org/10.1182/bloodadvances.2023012424","pdf_url":null,"source":{"id":"https://openalex.org/S2764683450","display_name":"Blood Advances","issn_l":"2473-9529","issn":["2473-9529","2473-9537"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Advances","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:11399641","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11399641","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11399641/pdf/main.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Adv","raw_type":"Text"},{"id":"pmid:38781315","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/38781315","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood advances","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1182/bloodadvances.2023012424","doi":"https://doi.org/10.1182/bloodadvances.2023012424","is_oa":true,"landing_page_url":"https://doi.org/10.1182/bloodadvances.2023012424","pdf_url":null,"source":{"id":"https://openalex.org/S2764683450","display_name":"Blood Advances","issn_l":"2473-9529","issn":["2473-9529","2473-9537"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Advances","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320307773","display_name":"GlaxoSmithKline","ror":"https://ror.org/01xsqw823"},{"id":"https://openalex.org/F4320308573","display_name":"Gilead Sciences","ror":"https://ror.org/056546b03"},{"id":"https://openalex.org/F4320309086","display_name":"Celgene","ror":"https://ror.org/0527yg379"},{"id":"https://openalex.org/F4320311600","display_name":"Regeneron Pharmaceuticals","ror":"https://ror.org/02f51rf24"},{"id":"https://openalex.org/F4320317235","display_name":"BeiGene","ror":"https://ror.org/012v2c923"},{"id":"https://openalex.org/F4320317544","display_name":"Incyte","ror":"https://ror.org/00cvzzg84"},{"id":"https://openalex.org/F4320319840","display_name":"Coherus Biosciences","ror":"https://ror.org/00mjj2d85"},{"id":"https://openalex.org/F4320327470","display_name":"Swedish Orphan Biovitrum","ror":"https://ror.org/04asvbz37"},{"id":"https://openalex.org/F4320328062","display_name":"MorphoSys","ror":"https://ror.org/00ew7rg06"},{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"},{"id":"https://openalex.org/F4320333647","display_name":"Kite Pharma","ror":"https://ror.org/05waa9105"},{"id":"https://openalex.org/F4320333648","display_name":"Pharmacyclics","ror":"https://ror.org/03hm8w204"},{"id":"https://openalex.org/F4320333682","display_name":"Ignyta","ror":"https://ror.org/05mmnft02"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4398250556.pdf","grobid_xml":"https://content.openalex.org/works/W4398250556.grobid-xml"},"referenced_works_count":31,"referenced_works":["https://openalex.org/W2013909810","https://openalex.org/W2030263904","https://openalex.org/W2065464657","https://openalex.org/W2119147717","https://openalex.org/W2124432094","https://openalex.org/W2169209759","https://openalex.org/W2470400696","https://openalex.org/W2529212447","https://openalex.org/W2598700764","https://openalex.org/W2742091838","https://openalex.org/W2795301499","https://openalex.org/W2907021708","https://openalex.org/W3048173383","https://openalex.org/W3105196097","https://openalex.org/W3135942249","https://openalex.org/W3210298727","https://openalex.org/W3210638874","https://openalex.org/W3213252454","https://openalex.org/W4205380135","https://openalex.org/W4206934925","https://openalex.org/W4212955993","https://openalex.org/W4224100224","https://openalex.org/W4280556984","https://openalex.org/W4283325073","https://openalex.org/W4283742913","https://openalex.org/W4307773195","https://openalex.org/W4310162498","https://openalex.org/W4379281282","https://openalex.org/W4380084502","https://openalex.org/W4386445852","https://openalex.org/W4389246936"],"related_works":["https://openalex.org/W4402262780","https://openalex.org/W4310106501","https://openalex.org/W4379981370","https://openalex.org/W3211809601","https://openalex.org/W4417008388","https://openalex.org/W4389233179","https://openalex.org/W4390048949","https://openalex.org/W4385667338","https://openalex.org/W4417007985","https://openalex.org/W4416664593"],"abstract_inverted_index":{"ABSTRACT:":[0],"This":[1],"phase":[2],"1b":[3],"study":[4],"evaluated":[5],"safety":[6],"and":[7,12,50,69,97,143,154,162,179,187,227,232],"efficacy":[8],"of":[9,136,202,235],"acalabrutinib,":[10],"venetoclax,":[11,51],"rituximab":[13,35],"(AVR)":[14],"in":[15,229],"treatment-naive":[16],"mantle":[17],"cell":[18],"lymphoma":[19],"(TN":[20],"MCL).":[21],"Patients":[22],"received":[23],"acalabrutinib":[24,72],"from":[25],"cycle":[26,43,45,54],"1":[27,153,178],"until":[28,48],"progressive":[29],"disease":[30,208],"(PD)":[31],"or":[32,47,116],"undue":[33],"toxicity,":[34],"for":[36,56,224],"6":[37],"cycles":[38],"with":[39,129,204],"maintenance":[40],"every":[41],"other":[42],"through":[44],"24":[46,57],"PD,":[49],"beginning":[52],"at":[53,152,177,242],"2,":[55],"cycles.":[58],"Twenty-one":[59],"patients":[60,76,89,203],"were":[61,147,157,169,182,194],"enrolled;":[62],"95.2%":[63,183],"completed":[64],"induction":[65],"(6":[66,93],"AVR":[67,219],"cycles)":[68],"47.6%":[70],"continued":[71],"maintenance.":[73],"Thirteen":[74],"(61.9%)":[75],"had":[77,90],"grade":[78,108],"3-4":[79],"adverse":[80],"events":[81],"(AEs),":[82],"most":[83],"commonly":[84],"neutropenia":[85],"(33.3%).":[86],"Seven":[87],"(33.3%)":[88],"COVID-19":[91,173,198],"infection":[92],"[28.6%]":[94],"serious":[95],"AEs":[96],"5":[98],"[23.8%]":[99],"deaths,":[100],"all":[101],"among":[102],"unvaccinated":[103],"patients).":[104],"There":[105],"was":[106,124,240],"no":[107],"\u22653":[109],"atrial":[110],"fibrillation,":[111],"ventricular":[112],"tachyarrhythmias,":[113],"major":[114],"hemorrhages,":[115],"tumor":[117],"lysis":[118],"syndrome.":[119],"Overall":[120],"response":[121],"rate":[122],"(ORR)":[123],"100%":[125,195],"(95%":[126,159,164,184,189],"CI,":[127,160,165,185,190],"83.9-100.0)":[128],"71.4%":[130],"complete":[131],"response.":[132],"With":[133],"median":[134,139],"follow-up":[135],"27.8":[137],"months,":[138],"progression-free":[140],"survival":[141,145],"(PFS)":[142],"overall":[144],"(OS)":[146],"not":[148],"reached.":[149],"PFS":[150],"rates":[151,176,234],"2":[155,180],"years":[156,181],"90.5%":[158],"67.0-97.5)":[161],"63.2%":[163],"34.7-82.0),":[166],"respectively;":[167,192],"both":[168,193],"95%":[170],"after":[171,196],"censoring":[172,197],"deaths.":[174,199],"OS":[175],"70.7-99.3)":[186],"75.2%":[188],"50.3-88.9),":[191],"Overall,":[200],"87.5%":[201],"available":[205],"minimal":[206],"residual":[207],"(MRD)":[209],"data":[210],"achieved":[211],"MRD":[212,236],"negativity":[213],"(10-6;":[214],"next-generation":[215],"sequencing)":[216],"during":[217],"treatment.":[218],"represents":[220],"a":[221],"chemotherapy-free":[222],"regimen":[223],"TN":[225],"MCL":[226],"resulted":[228],"high":[230,233],"ORR":[231],"negativity.":[237],"The":[238],"trial":[239],"registered":[241],"www.ClinicalTrials.gov":[243],"as":[244],"#NCT02717624.":[245]},"counts_by_year":[{"year":2026,"cited_by_count":9},{"year":2025,"cited_by_count":14},{"year":2024,"cited_by_count":2},{"year":2022,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2024-05-24T00:00:00"}